Salarius Announces Proposed Public Offering of Common Stock
29 juil. 2020 16h15 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical Trial
29 juil. 2020 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals Announces Move to New Corporate Offices at Texas Medical Center
28 juil. 2020 08h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals Names Nadeem Mirza, M.D., M.P.H., as Senior Vice President Clinical Development
23 juil. 2020 08h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 23, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
Salarius Pharmaceuticals Invited to Present Seclidemstat Research at Meeting of the Pediatric Oncology Subcommittee of the Food and Drug Administration’s Oncologic Drugs Advisory Committee
02 juin 2020 09h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, June 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program
27 mai 2020 08h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results
14 mai 2020 16h05 HE
|
Salarius Pharmaceuticals, Inc.
Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020 Conference Call and Live Audio Webcast Scheduled for Today, May 14, 2020, at...
Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program
14 mai 2020 08h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced...
Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results
07 mai 2020 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting
29 avr. 2020 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, April 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...